GAITHERSBURG, Md., April 16 /PRNewswire/ -- MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.
"Through innovative approaches, MedImmune strives to apply novel treatment paradigms to help extend and improve the lives of people with cancer and we are proud to share data from our increasingly broad oncology portfolio at this year's meeting," said Klaus Bosslet, vice president, oncology research
MedImmune research scheduled to be presented includes:
- Fully human anti-interleukin-6 (IL-6) monoclonal antibody suppresses the growth of human tumor xenograft in vivo (Poster Session: Monoclonal Antibodies 1, abstract 2432, poster section 18) – Monday, April 19 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- Cytotoxicity of the anti-CD22 immunotoxin HA22 against pediatric acute lymphoblastic leukemia (ALL) (Poster Session: Pediatric Brain Tumors and Leukemia, abstract 4356, poster section 19) – Tuesday, April 20 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- Combination of MEDI3617, a fully human anti-angiopoietin 2 monoclonal antibody, with inhibitors of the VEGF pathway enhances antitumor activity in vivo (Poster Session: Novel/New Antiangiogenic Therapeutic Approaches, abstract 1364, poster section 15) – Monday, April 19 from 9:00 a.m. – 12:00 p.m. in Exhibit Hall A-C.
- EphA2-targeting antibody-gelonin specifically binds and kills target-expressing tumor cells, including multi-drug resistant (MDR) lines (Poster Session: Antibody Technologies, abstract 4399, poster section 21) – Tuesday, April 20 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- EphB4 promotes or suppresses Ras/ERK pathway depending on cellular contexts: implications for EphB4 as a cancer target (Poster Session: Intracellular Signaling 1, abstract 307, poster section 10) – Sunday, April 18 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA (Poster Session: Modified Antibodies and Oncolytic Viruses, abstract 2584, poster section 24) – Monday, April 19 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain antibody for treatment of gastrointestinal adenocarcinomas (Poster Session: Immunomodulatory Agents and Interventions, abstract 5625, poster section 31) – Wednesday, April 21 from 8:00 a.m. – 11:00 a.m. in Exhibit Hall A-C.
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody (Poster Session: Monoclonal Antibodies 2, abstract 5338, poster section 19) – Wednesday, April 21 from 8:00 a.m. – 11:00 a.m. in Exhibit Hall A-C.
- Molecular characterization of circulating tumor cells using fluidigm biomark dynamic array (Poster Session: Molecular Classification of Tumors, abstract 796, poster section 30) – Sunday, April 18 from 2:00 p.m. – 5:00 p.m. in Exhibit Hall A-C.
- Application of circulating tumor cells and circulating cell-free DNA to assess the pharmacodynamic response to chemotherapy in xenograft models (Poster Session: Biomarkers Predictive of Response to Therapy 2, abstract 3736, poster section 33) – Tuesday, April 20 from 9:00 a.m. – 12:00 p.m. in Exhibit Hall A-C.
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com .